Pneumatica Bio is a Melbourne-based biotechnology start-up pioneering the prediction of novel therapeutics.
We unite biology, engineering, and computation to transform how next-generation therapeutics are designed and developed. Our platform accelerates discovery, reduces risk, and helps ensure that breakthrough therapies reach patients faster.
THE
FUTURE
IS
PREDICTIVE
Mission
We predict therapeutic function without the need for animal or human trials.
The Problem
The pathway for new therapeutics is long and treacherous. It takes more than a decade and hundreds of millions of dollars for a therapy to reach the market. Despite this, 90% of drugs that make it as far as clinical trials still fail. Each failure represents not just wasted resources, but a story of lost time and missed opportunity for patients.
The Opportunity
A new generation of therapeutic modalities is reshaping medicine. Emerging technologies, like mRNA-encapsulating lipid nanoparticles, are rewriting the rules, enabling complex payloads to be delivered directly to target cells with minimal toxic side effects.
But the clinical pathway is still broken. Using preclinical data to predict performance in the complex environment of the human body is unreliable. This leaves therapeutic design dependent on trial and error – wasting time, capital, and opportunity.
The reason is clear: we’re still using the development playbook built for small molecule drugs. Next-generation therapeutics are fundamentally different, and demand a new way of thinking. By embracing their unique biological and physical behaviour, we can unlock their full potential and bring therapies to patients faster.
Our Vision
At Pneumatica Bio, we’re writing a new playbook. We believe that the future is predictive. By uniting fields and perspectives, we move faster, smarter, and together.
We employ sophisticated and automated biological assays in concert with cutting-edge computational, mathematical and statistical techniques to predict the biodistribution of next-generation therapeutics. Our efficient and high-throughput technical platform mitigates financial risks in clinical trials and streamlines drug development pipelines.
We will realise the potential of these revolutionary therapies, and turn preclinical promise into real impact for patients.
Our Approach
Robotics and
Automation
Biology is the bottleneck, not drug discovery.
Our automated experimental platform means we can scale up data generation to ensure our predictive inputs are cost-effective and rich in biological information.
Next-Gen
Therapeutics
The next generation of therapies requires a next-generation playbook.
Our techniques are tailored to the unique behaviour and interactions of next-gen therapeutics like nanoparticles and biologics.
Accountable
Intelligence
Decision making in drug development needs to be transparent.
Our predictive pipeline blends mechanistic computational models with AI/ML for interpretable predictions that encode humanity’s knowledge of biology and physics.
Therapeutic
Insight
Off-target responses are as important as target response.
Our proprietary quantitative insights allow us to predict drug response throughout the body – both at the target site, and in off-target tissues and organs.
If you want to know more details about our approach, reach out for a chat!
About
Pneumatica Bio is a Melbourne-based biotechnology start-up pioneering clinical prediction of novel therapeutics.
The future of medicine is dynamic and increasingly multidisciplinary. Our Founders bring together expertise in biological automation, software development, biomedical engineering, computational modelling, and data science.
With backgrounds spanning academia and industry, our team has published influential scientific research, secured competitive grants, and pioneered quantitative and standardised approaches for evaluating next-generation therapeutics. Combined with experience in both emerging and established technology companies in Australia and abroad, we are uniquely positioned to turn innovation into impact.
See more about our Team here.